UY27388A1 - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
UY27388A1
UY27388A1 UY27388A UY27388A UY27388A1 UY 27388 A1 UY27388 A1 UY 27388A1 UY 27388 A UY27388 A UY 27388A UY 27388 A UY27388 A UY 27388A UY 27388 A1 UY27388 A1 UY 27388A1
Authority
UY
Uruguay
Prior art keywords
compounds
new compounds
formula
preparation
present
Prior art date
Application number
UY27388A
Other languages
English (en)
Inventor
Takehiro Okada
Fumio Watanabe
Mikio Taniguchi
Toshihiko Fujii
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY27388A1 publication Critical patent/UY27388A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula I, con actividad anti-tumoral, en donde R1, R2, R3, R4, R5 y n son tal como se describen en la descripción y las reivindicaciones y las sales farmacéuticamente aceptables de las mismas. La presente invención concierne también a la composición farmacéutica que comprende compuestos de fórmula (I), el uso de compuestos de fórmula (I) para la preparación de medicamentos y procesos para la preparación de compuestos (I).
UY27388A 2001-07-19 2002-07-17 Nuevos compuestos UY27388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01117410 2001-07-19

Publications (1)

Publication Number Publication Date
UY27388A1 true UY27388A1 (es) 2003-01-31

Family

ID=8178073

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27388A UY27388A1 (es) 2001-07-19 2002-07-17 Nuevos compuestos

Country Status (30)

Country Link
US (1) US6737409B2 (es)
EP (1) EP1412328B1 (es)
JP (1) JP2004534859A (es)
KR (2) KR100611540B1 (es)
CN (1) CN1553897A (es)
AR (1) AR036175A1 (es)
AT (1) ATE341537T1 (es)
BR (1) BR0211289A (es)
CA (1) CA2453987A1 (es)
CO (1) CO5550462A2 (es)
DE (1) DE60215179T2 (es)
DK (1) DK1412328T3 (es)
ES (1) ES2272763T3 (es)
GT (1) GT200200154A (es)
HR (1) HRP20040043A2 (es)
HU (1) HUP0401253A2 (es)
IL (1) IL159890A0 (es)
MX (1) MXPA04000577A (es)
MY (1) MY127718A (es)
NO (1) NO20040198L (es)
NZ (1) NZ530655A (es)
PA (1) PA8551001A1 (es)
PE (1) PE20030258A1 (es)
PL (1) PL367682A1 (es)
PT (1) PT1412328E (es)
RU (1) RU2296750C2 (es)
SI (1) SI1412328T1 (es)
UY (1) UY27388A1 (es)
WO (1) WO2003008378A1 (es)
ZA (1) ZA200400334B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
AU2003228354B8 (en) 2002-03-22 2010-03-04 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
MXPA06013998A (es) * 2004-06-02 2007-02-08 Hoffmann La Roche Sintesis de ester de alquilo de acido amino-alcoxi-heptanoico.
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
JP2008523001A (ja) * 2004-12-13 2008-07-03 エフ．ホフマン−ラ ロシュ アーゲー ３−ピロリジン−２−イル−プロピオン酸誘導体を製造するための新規な方法
CA2590431A1 (en) * 2004-12-13 2006-06-22 F. Hoffmann-La Roche Ag Novel pharmaceutical composition containing at least one dolastatin 10 derivative
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
KR20070087025A (ko) * 2005-01-13 2007-08-27 에프. 호프만-라 로슈 아게 유용한 2치환 아민의 신규 1단계 합성법
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
US20080003652A1 (en) * 2006-06-28 2008-01-03 Hans Iding Novel enzymatic process for the manufacture of Boc-Dap-Oh priority to related application(s)
ES2579323T3 (es) 2007-07-16 2016-08-09 Genentech, Inc. Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
CL2009000062A1 (es) 2008-01-31 2010-05-14 Genentech Inc Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas.
US8609105B2 (en) 2008-03-18 2013-12-17 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
ES2528956T3 (es) 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
JP5933562B2 (ja) 2010-09-29 2016-06-15 シアトル ジェネティックス， インコーポレイテッド Ｎ−カルボキシアルキル−アウリスタチンおよびその使用
CN103764667B (zh) * 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
EA201391756A1 (ru) * 2011-05-27 2014-05-30 Амбркс, Инк. Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
MX345538B (es) * 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
CA2885973C (en) 2012-09-20 2017-09-05 Celltrion, Inc. Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same
CN106255513B (zh) 2013-12-27 2022-01-14 酵活有限公司 用于药物偶联物的含磺酰胺连接系统
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CN105949277B (zh) * 2015-05-05 2019-03-01 成都永泰诺科技有限公司 一种抗肿瘤化合物及其用途
CN108779146B (zh) * 2016-03-29 2022-03-18 东丽株式会社 肽衍生物及其用途
CN109021065B (zh) * 2017-06-08 2021-10-01 复旦大学 一种制备海兔毒素Dolastatin10的方法
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides

Also Published As

Publication number Publication date
PT1412328E (pt) 2007-01-31
PA8551001A1 (es) 2003-09-17
ZA200400334B (en) 2005-06-29
WO2003008378A1 (en) 2003-01-30
CO5550462A2 (es) 2005-08-31
CN1553897A (zh) 2004-12-08
ES2272763T3 (es) 2007-05-01
AR036175A1 (es) 2004-08-18
HRP20040043A2 (en) 2004-08-31
MXPA04000577A (es) 2004-04-20
US6737409B2 (en) 2004-05-18
DE60215179T2 (de) 2007-10-18
CA2453987A1 (en) 2003-01-30
EP1412328A1 (en) 2004-04-28
KR20040023661A (ko) 2004-03-18
RU2004105145A (ru) 2005-07-10
PL367682A1 (en) 2005-03-07
RU2296750C2 (ru) 2007-04-10
EP1412328B1 (en) 2006-10-04
ATE341537T1 (de) 2006-10-15
GT200200154A (es) 2003-05-16
JP2004534859A (ja) 2004-11-18
KR100611540B1 (ko) 2006-08-10
SI1412328T1 (sl) 2007-02-28
IL159890A0 (en) 2004-06-20
DK1412328T3 (da) 2007-02-12
KR20060057652A (ko) 2006-05-26
DE60215179D1 (de) 2006-11-16
BR0211289A (pt) 2004-08-03
MY127718A (en) 2006-12-29
PE20030258A1 (es) 2003-03-19
NO20040198L (no) 2004-02-19
NZ530655A (en) 2006-08-31
US20030055002A1 (en) 2003-03-20
HUP0401253A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
UY27388A1 (es) Nuevos compuestos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY28510A1 (es) Compuestos quimicos
ECSP034444A (es) Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina
PA8432901A1 (es) Compuestos de piridilpirrol
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
ECSP045003A (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos.
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
UY27368A1 (es) Nuevos compuestos
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
RS99804A (en) Novel compounds and their use
UY29896A1 (es) Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
UY27593A1 (es) Nuevos compuestos
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY27980A1 (es) Indoles 2,7-sustituidos
ECSP034754A (es) Derivados de beta-carbolina y su uso farmaceutico contra depresion y ansiedad
AR025046A1 (es) Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141226